MARKETS PERPS LIVE98

Cash

Trending Elections Politics Culture Sports Crypto Commodities Climate Economics Mentions

Finance

Predict Live98 AccountSocial

Product

Kalshi Pro Perpetual Futures Markets Incentive program Institutions API & developers

Company

About Kalshi Research Blog Careers Policy Center Brand Kit

Help

Help Center FAQ Fee schedule Trading hours Regulatory Trust Center

© 2026 Kalshi Inc. · All rights reserved

Privacy Data Terms of Service Trading Prohibitions FAQ for Finance Professionals

Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.

Public Companies Hub

Industries

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)

Yes

1.16x

No

4.73x

$1,747 vol1 market

FDA decision: Venglustat by Sanofi (this year)

Yes

1.18x

No

4.13x

$521 vol1 market

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

Yes

1.33x

No

2.81x

$487 vol1 market

FDA decision: Ivonescimab by Summit Therapeutics (this year)

Yes

1.44x

No

2.46x

$5,844 vol1 market

FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (this year)

Yes

1.20x

No

3.66x

$468 vol1 market

FDA decision: Bepirovirsen by GlaxoSmithKline (this year)

Yes

1.19x

No

3.80x

$1,825 vol1 market

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

Yes

1.07x

No

7.25x

$831 vol1 market